Amicus Therapeutics Total Revenue

Amicus Therapeutics (FOLD) currently reports a total revenue of $630M as of December 2025. That compares with $530M in the prior-year period — up 20.0% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Amicus Therapeutics's total revenue history and peer comparisons.

Amicus Therapeutics's total revenue increased from $530M to $630M — a 20.0% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amicus Therapeutics's total revenue of $630M is lower than the Healthcare sector average of $110B. That is roughly 99.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Amicus Therapeutics reported $630M in total revenue as of December 2025. That compares with $530M in the prior-year period — up 20.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $630M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Amicus Therapeutics, and consider following FOLD for alerts when major investors trade the stock.